NASDAQ:LOGC

LogicBio Therapeutics (LOGC) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$2.07
$2.07
50-Day Range
$2.04
$2.07
52-Week Range
$0.26
$3.77
Volume
N/A
Average Volume
652,526 shs
Market Capitalization
$68.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
LOGC stock logo

About LogicBio Therapeutics Stock (NASDAQ:LOGC)

LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

LOGC Stock News Headlines

RVVTF Revive Therapeutics Ltd.
LogicBio's IPO: What You Need To Know
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
AstraZeneca acquires local startup at 660% premium
LogicBio Therapeutics Inc
Recap: LogicBio Therapeutics Q2 Earnings
LogicBio Therapeutics Inc - Stock Quote LOGC
See More Headlines
Receive LOGC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LogicBio Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
4/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:LOGC
Fax
N/A
Employees
62
Year Founded
N/A

Profitability

Net Income
$-40,030,000.00
Net Margins
-246.71%
Pretax Margin
-246.71%

Debt

Sales & Book Value

Annual Sales
$5.41 million
Book Value
$0.48 per share

Miscellaneous

Free Float
30,293,000
Market Cap
$68.23 million
Optionable
Not Optionable
Beta
4.61
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Frederic  Chereau M.B.A.Mr. Frederic Chereau M.B.A. (Age 55)
    Pres, CEO & Director
    Comp: $793.2k
  • Dr. Mark A. Kay M.D. (Age 64)
    Ph.D., Co-Founder, Chairman of Scientific Advisory Board & Independent Director
    Comp: $107.5k
  • Dr. Daniel J. Gruskin M.D. (Age 50)
    Chief Medical Officer
    Comp: $577.48k
  • Dr. Leszek Lisowski M.B.A.
    Ph.D., Co-Founder & Member of Scientific Advisory Board
  • Dr. Adi Barzel Ph.D.
    Co-Founder
  • Mr. Joshua Blacher (Age 49)
    Interim CFO, Principal Financial Officer & Principal Accounting Officer
  • Dr. Matthias Hebben Ph.D.
    Global VP & Head of Technology Devel.
  • Dr. Mariana Nacht Ph.D. (Age 58)
    Chief Scientific Officer
  • Ms. Andrea Paul J.D. (Age 41)
    Gen. Counsel & Corp. Sec.
  • Ms. Grace Lochhead
    VP & Head of HR

LOGC Stock Analysis - Frequently Asked Questions

How were LogicBio Therapeutics' earnings last quarter?

LogicBio Therapeutics, Inc. (NASDAQ:LOGC) posted its earnings results on Monday, November, 15th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by $0.01. The company had revenue of $2.12 million for the quarter, compared to analysts' expectations of $5.02 million. LogicBio Therapeutics had a negative trailing twelve-month return on equity of 115.29% and a negative net margin of 246.71%.

What other stocks do shareholders of LogicBio Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other LogicBio Therapeutics investors own include Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), Acceleron Pharma (XLRN), Stoke Therapeutics (STOK), Precision BioSciences (DTIL), Micron Technology (MU), Homology Medicines (FIXX) and II-VI (IIVI).

When did LogicBio Therapeutics IPO?

LogicBio Therapeutics (LOGC) raised $77 million in an IPO on Friday, October 19th 2018. The company issued 5,800,000 shares at a price of $12.50-$14.00 per share. Jefferies, Barclays and William Blair served as the underwriters for the IPO and Chardan was co-manager.

This page (NASDAQ:LOGC) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners